Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ERYP.PA (Common Stock)
ExchangeParis (Euro)
Price€28.25
Change (%) Stock is Down 0.7 (2.42%)
Volume49,915
Data as of 06/27/17 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
07-Jun-2017ERYTECH Pharma: Annual General Meeting of June 27, 2017
Availability of documents related to the annual general meeting LYON, France--(BUSINESS WIRE)--Jun. 7, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), the French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announced today the modalities for making available the documents for the Annual General Meeting of June 27, 2017. ... 
 Printer Friendly Version
05-Jun-2017ERYTECH Pharma: Information related to total number of voting rights and shares composing the share capital –May 31st, 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jun. 5, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment C ISIN Code : FR0011471135 website : www.erytech.com     ... 
 Printer Friendly Version
18-May-2017ERYTECH Provides Business Update and Financial Highlights For Q1 2017
Conference call and webcast on Friday, May 19th at 15:00 pm CET/09:00 am EDT Reported positive Phase 2b data in metastatic Pancreatic Cancer for eryaspase, demonstrated significant improvement in both progression-free survival (PFS) and overall survival (OS) Launched an investigator-initiated Phase 2 study of eryaspase (GRASPA®) in Acute Lymphoblastic Leukemia (ALL) Presented promising pr... 
 Printer Friendly Version
17-May-2017Erytech to Hold Q1 2017 Business Update Conference Call on May 19th, 2017
LYON, France--(BUSINESS WIRE)--May 17, 2017-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it will release its financial results and business update for the quarter ended March 31, 2017 on Thursday, May 18, 2017 aft... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
09/11/17
Second Quarter and Half-Year 2017 Financial Results and Business Update: Press Release: Monday, September 11, 2017 (after market)
09/12/17 3:00 p.m. CET
Second Quarter and Half-Year 2017 Financial Results and Business Update: Conference Call
11/13/17
Third Quarter 2017 Financial Results and Business Update: Press Release: Monday, November 13, 2017 (after market)
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Top